Daclizumab therapy for multiple sclerosis - Wikidata - awgldk - TriplyDB

Daclizumab therapy for multiple sclerosis

Daclizumab therapy for multiple sclerosis

http://www.wikidata.org/entity/Q27022517

about

Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis The effects of interleukin-2 on immune response regulation.The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.Infection risk in patients on multiple sclerosis therapeutics.Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis In search of magic bullets: the golden age of immunotherapeutics.Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.Cutaneous adverse events in multiple sclerosis patients treated with daclizumab Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.Cytokine Therapies in Neurological Disease.Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.The role of natural killer cells in multiple sclerosis and their therapeutic implications.Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.Infectious complications of immune modulatory agents.Multiple sclerosis treatment and infectious issues: update 2013.The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Daclizumab for the treatment of multiple sclerosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Daclizumab: A Review in Relapsing Multiple Sclerosis.Daclizumab for the treatment of relapsing-remitting multiple sclerosis.Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Pharmacodynamic effects of daclizumab in the intrathecal compartment.New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis.Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

P2860

Q27693249-2EB1723C-D000-4EA8-9501-A40C9076B485 Q30252875-B0118CF4-1FDC-4001-AEBC-D71E277C2FDF Q30730505-16B954BD-648F-4267-920C-48BD96C609EA Q30908652-44389C7D-3DCE-4D0C-902B-22245A2D4835 Q33589947-64222341-81B8-4003-962E-4353767BDCA0 Q34356481-EF19E829-701D-410E-942F-84B52D067C3B Q35012335-D94B5997-6C7D-4626-8BC2-69C40EE10953 Q35619174-32D6CE12-7BCE-46B5-A76A-1E7106DAB99F Q36521247-59CEDD35-22E7-4F7B-8F53-CF78D368AD50 Q36585726-77953A69-E8B0-4D2A-96F8-C2C467325518 Q36691970-523F0416-2E3B-4C66-9C59-EF6C4D627676 Q36975701-1503ABAD-C3B3-46EC-A731-A38413FF1E24 Q37030744-7C1886FD-CF2C-4D8C-9BC9-3C0FCC7686E5 Q37136498-3542ADD7-8AF6-445C-972A-47B2D97018B9 Q37286272-E2B70C2B-D9BC-4845-856A-8C3D5A29E418 Q37459065-4DE9E539-F752-4738-A4B0-BFE9B51066B7 Q37502636-3AB1728A-5463-4004-A7C4-96D03082BBC7 Q37558843-97DE750B-357C-496B-B9F2-D504566FA82B Q37657070-B5C82CBB-ADD5-4C54-8691-628E7FBF87DF Q38089599-65A8038B-8065-4486-B36F-22882A1DAC8B Q38111620-201A0EE9-C573-44EE-B5D8-98A80C7F270F Q38114422-D8ED107B-B50D-4989-A509-408D681118FC Q38144976-42FC5F65-44D9-4A6C-A6E5-DA036060510D Q38153471-B83198DA-F693-4D9A-A72E-0ABC2A550E4A Q38291845-CB6BDBA1-4FA2-4B0B-B9E6-FABCFCD46668 Q38315992-91356394-2645-443D-9C64-A5C39A9DFF3D Q38364547-07B7EE5E-6BF5-433A-BEB6-A334F082DC20 Q38397484-C604D81A-5606-4C2B-8164-2B14773457DA Q38604207-B38D6A29-1A23-4138-8535-30A0ECF8E766 Q38837294-51D1AE39-9EC3-4DCE-B469-311A766A30BD Q39021942-B7A7FA86-2138-458F-9570-F00EBD6E8D73 Q39140303-0501511A-5B0A-4351-BC40-C2044160E65A Q39175716-B166A7CD-FF3C-477F-8B72-DA357B8D66AE Q39434495-D2224244-F547-49B2-9AB1-B0BFA398D982 Q40962441-A41A609D-D1E4-4281-92F7-40D4524C7B21 Q41459008-9B9E1ECE-895E-4D48-9E8E-CCC7228B3BC9 Q43905322-1283F5FC-4BE8-4095-9FA1-71490B5837E6 Q45066717-6658A5FC-099C-4172-9EF0-2B01A755FEDB Q47959279-64ABB992-6A7C-45FC-B5D2-47979FCE9768 Q50871333-507CF289-B7C2-46F9-A58F-8F19C811B464

P2860

Daclizumab therapy for multiple sclerosis

http://www.wikidata.org/entity/Q27022517

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Daclizumab therapy for multiple sclerosis

@ast

Daclizumab therapy for multiple sclerosis

@en

Daclizumab therapy for multiple sclerosis

@nl

type

label

Daclizumab therapy for multiple sclerosis

@ast

Daclizumab therapy for multiple sclerosis

@en

Daclizumab therapy for multiple sclerosis

@nl

prefLabel

Daclizumab therapy for multiple sclerosis

@ast

Daclizumab therapy for multiple sclerosis

@en

Daclizumab therapy for multiple sclerosis

@nl

P1433

Q27022517-2213CA30-E8D8-41D5-9278-5A9F23D4DACC

P1476

Q27022517-F3804662-5A15-4D53-84E6-779836AEE196

P2093

Q27022517-DF3199D3-5438-4D75-96A1-FF0000CB59C3

P2860

Q27022517-06B39F76-10D4-40A4-8193-938AA2257733

Q27022517-09FE94F5-C725-4B69-83EA-145A21E59310

Q27022517-0A5BDA92-B14D-46F3-A272-C69D357ABE40

Q27022517-0AC0D4AD-333D-46E7-81F8-855BD15DC9AC

Q27022517-0AE5347F-4890-4FE1-AD40-EB19254F5A60

Q27022517-0B4AF316-FF94-4421-8BEA-ABA5EC18E4FC

Q27022517-0F64A3F8-C685-47DB-A763-CAEADF4F4BBB

Q27022517-0F785889-31AA-4CE6-B6CF-8EF85DADDEFC

Q27022517-1267B08D-9875-4F74-BC70-9484BD976D1E

Q27022517-18F05562-A5A7-4413-AB00-91E83BE4841C

P2888

Q27022517-E7B10FC3-7370-4337-99ED-7FA3C6546EE2

P304

Q27022517-C8951859-5BB2-4545-BB9D-C249EC2D8B80

P31

Q27022517-A605F3BF-0C82-4D88-98A7-9F984FC32CBC

P3181

Q27022517-03FA3CBF-1C2D-4315-92EE-B2FBA49954E7

P356

Q27022517-C5E11B6C-76F0-4DF7-AC01-6198EB2C8B9B

P407

Q27022517-55C4FF15-E9A4-42F9-80FE-7BCFA713E3EF

P433

Q27022517-2766B7FF-EB94-4567-8386-1DF98AE942C8

P478

Q27022517-A726A924-25D4-40B6-99C1-F48CCAC0EE01

P577

Q27022517-2EDB76F7-FBEE-46DF-91F4-08C1E55A3D4B

P6179

Q27022517-B6EA7AE7-9616-4A22-8C77-823F4125C97B

P698

Q27022517-EB9AB508-ACDC-494D-9B46-0836677B3BC8

P921

Q27022517-270F4978-2C3F-4C6B-AD89-AC1C72A8F206

P932

Q27022517-E7C46215-ECC6-4045-8F54-A3837C0042F7

P3181

P356

S13311-012-0147-4

P1433

Neurotherapeutics

P1476

Daclizumab therapy for multiple sclerosis

@en

P2093

Bibiana Bielekova

http://www.w3.org/2001/XMLSchema#string

P2860

Daclizumab for relapsing remitting multiple sclerosis

Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor

Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting

Structural basis for NKG2A/CD94 recognition of HLA-E.

A humanized antibody that binds to the interleukin 2 receptor

Natural killer cells and autoimmunity

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors

Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment

Risk alleles for multiple sclerosis identified by a genomewide study

P2888

s13311-012-0147-4

P304

55-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3887981

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S13311-012-0147-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011949884

http://www.w3.org/2001/XMLSchema#string

P698

23055048

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3557356

http://www.w3.org/2001/XMLSchema#string